MacroGenics Enters License Agreement with Gilead Sciences to Develop and Commercialize Four DART Products

Loading...
Loading...
MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced it has entered into a license agreement with Gilead Sciences, Inc.
GILD
for the development and commercialization of Dual-Affinity Re-Targeting (DART™) products directed at up to four undisclosed targets.  MacroGenics' DART technology is a proprietary, bi-specific antibody platform in which a single recombinant molecule is able to target two different antigens. "We look forward to building a long-term collaboration with MacroGenics, a leader in the development of bi-specific antibodies, which represents a promising new area of research," said Roy D.
See full press release
Posted In: NewsGuidanceContractsManagementGlobal
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...